Category: Healthcare and Medical News

Direct Biologics Announces FDA Approval for Proceeding With Second ExoFlo IND for Post-Acute COVID-19 Syndrome and Chronic Post-COVID-19 Syndrome
Press Release Jul 20, 2021
Direct Biologics Announces FDA Approval for Proceeding With Second ExoFlo IND for Post-Acute COVID-19 Syndrome and Chronic Post-COVID-19 Syndrome

Extracellular Vesicle Isolate Product ExoFlo Shows Strong Potential to Treat COVID-19, Post-Acute COVID-19 Syndrome, and Chronic Post-COVID-19 Syndrome; 60-patient trial to be conducted nationally at ambulatory infusion sites
Direct Biologics Announces FDA Acceptance of IND Application for a Phase I/II Clinical Trial Studying ExoFlo for Acute Respiratory Distress Syndrome
Press Release Jul 14, 2021
Direct Biologics Announces FDA Acceptance of IND Application for a Phase I/II Clinical Trial Studying ExoFlo for Acute Respiratory Distress Syndrome

Fourth IND Application approval for investigational extracellular vesicle (EV) product ExoFlo
Direct Biologics Granted FDA Approval of Third IND Application for the Use of ExoFlo in Mild-to-Moderate COVID-19 Infusion Therapy
Press Release Jun 29, 2021
Direct Biologics Granted FDA Approval of Third IND Application for the Use of ExoFlo in Mild-to-Moderate COVID-19 Infusion Therapy

Extracellular vesicle product ExoFlo clinical trials to address early-stage COVID-19.
Direct Biologics Receives FDA Approval to Proceed with Second ExoFlo IND for Post-Acute COVID-19 Syndrome and Chronic Post-COVID-19 Syndrome
Press Release Jun 9, 2021
Direct Biologics Receives FDA Approval to Proceed with Second ExoFlo IND for Post-Acute COVID-19 Syndrome and Chronic Post-COVID-19 Syndrome

Extracellular Vesicle Isolate Product ExoFlo Shows Strong Potential to Treat COVID-19, Post-Acute COVID-19 Syndrome, and Chronic Post-COVID-19 Syndrome; 60-patient trial to be conducted nationally at ambulatory infusion sites
Direct Biologics Announces New Advanced Tool in Regenerative Medicine with Launch of AmnioWrap™ Placental Allograft
Press Release Jan 12, 2021
Direct Biologics Announces New Advanced Tool in Regenerative Medicine with Launch of AmnioWrap™ Placental Allograft

New Allograft Joins Market Leading ExoFlo™ Extracellular Vesicles in Direct Biologics Product Line
Direct Biologics Announces First Patient Treated Under Phase II Expanded Access Protocol Using ExoFlo™ to Treat COVID-19
Press Release Dec 30, 2020
Direct Biologics Announces First Patient Treated Under Phase II Expanded Access Protocol Using ExoFlo™ to Treat COVID-19

The expanded Access Program provides a pathway for patients to gain access to treatment with ExoFlo outside of the active Phase II research clinical trial.
Direct Biologics Granted Expanded Access by FDA for ExoFlo™ in the Treatment of COVID-19
Press Release Oct 13, 2020
Direct Biologics Granted Expanded Access by FDA for ExoFlo™ in the Treatment of COVID-19
Press Release Sep 9, 2020
Direct Biologics Initiates Patient Enrollment in the Phase II EXIT COVID-19 Clinical Trial

Phase II Clinical Trial Initiated for ExoFlo Extracellular Vesicles in the Treatment of COVID-19
Press Release Aug 27, 2020
New Data Suggest ExoFlo is Poised for a Quantum Leap in the Fight Against COVID-19